- active not recruitingPHASE3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This study is looking at different ways of giving a medicine called donanemab for early Alzheimer's disease. Researchers want to see how different doses affect side effects and which patients might be more likely to experience them. It's for adults aged 60-85.
United States · United Kingdom - active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
This study is testing a new medication called donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow memory and thinking problems. It's a key step in understanding potential new treatments for this condition.
Argentina · Australia · China - recruiting
Serotonin Release in Premotor and Motor PD
This study aims to better understand Parkinson's disease by using special brain scans. Researchers hope to find a 'biomarker' – a sign of the disease – which could help develop new medicines to slow down Parkinson's symptoms.
United Kingdom - recruiting
Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR
This study looks into how inflammation might play a role in Parkinson's disease. Researchers will use special scans and tests to understand why inflammation happens and how it affects the disease, hoping to find new ways to help patients in the future.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease
This study is looking at how different amounts of the drug donanemab affect swelling in the brain (ARIA-E) and reduce amyloid — a protein linked to Alzheimer's disease. It's for adults in the early stages of Alzheimer's.
Italy - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease
This study is an ongoing look at a medicine called latozinemab for people with brain diseases that worsen over time, like Alzheimer's. It checks how safe it is and if it helps participants over a longer period.
Germany · Portugal · Italy - recruiting
Molecular and Functional Imaging in Monogenic PD.
This study uses special brain scans to understand Parkinson's disease better, especially in people with a genetic link. The goal is to find ways to measure the disease and help develop new medicines to slow down symptoms.
United Kingdom - recruiting
Longitudinal Investigation of I2BS in PD
This study aims to find ways to measure Parkinson's disease progression using special brain scans and spinal fluid tests. Researchers hope to understand the disease better and help develop new treatments to slow down its effects. It involves multiple visits over a year in London.
United Kingdom